More Business News:
BioNJ to Kick Off 2010 with 17th Annual Meeting to Support New Jersey’s Biotech Innovation
More Than 400 Attendees Expected for This Year's Meeting; Featured Speakers include Lilly's John Johnson, BIO's James Greenwood
TRENTON, N.J. -- BioNJ, New Jersey's trade association for the biotechnology community, will hold its 17th Annual Dinner Meeting, Awards Program and Networking Event on Thursday, January 28, 2010 from 5:00 p.m. to 10:00 p.m. at the Hilton East Brunswick. The meeting will bring together New Jersey's biotechnology community to celebrate the efforts and contributions of the state's companies to advance scientific innovation and improve patient care.
This year's meeting is expected to attract more than 400 attendees from across New Jersey's biotechnology community. The event will feature prepared remarks by John H. Johnson, President of Global Oncology and Senior Vice President of Eli Lilly and Company (formerly Chief Executive Officer of ImClone Systems), and The Honorable James Greenwood, President and CEO of BIO.
"This year's Annual Meeting will serve as an opportunity to recognize the efforts and accomplishments made by New Jersey's biotechnology community and to look to the future," said Debbie Hart, President of BioNJ. "We are fortunate to have two high-powered speakers and we look forward to hearing the insights and viewpoints that will be shared by John Johnson and Jim Greenwood regarding crucial issues that are impacting our industry today and in the year ahead."
About John H. Johnson, Eli Lilly and Company
John H. Johnson has more than two decades of executive and operational management experience in the biopharmaceutical and healthcare industries. Mr. Johnson currently serves as Senior Vice President and President, Global Oncology Business Unit, Eli Lilly and Company. Prior to this appointment in November 2009, he served as Chief Executive Officer of ImClone Systems since August 2007 and was also a member of ImClone's Board of Directors until the Company became a wholly-owned subsidiary of Lilly in November 2008.
Prior to joining ImClone, Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit. In this executive role, he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses, including Centocor, Inc., Ortho Biotech Products, L.P. and the Worldwide Strategic Marketing group.
Mr. Johnson began his healthcare career with Pfizer in 1983 where he held positions of increasing responsibility in sales and sales management. He joined Johnson & Johnson in 1988 to help lead their entry into the Anti-Infectives business. Mr. Johnson advanced through positions of increasing responsibility with Ortho-McNeil, including leading the commercial groups responsible for the development of sales, marketing and new product strategies of several of the company's flagship brands, including LEVAQUIN®, ULTRAM® and TOPAMAX®. In 2000, he left Johnson & Johnson to assume the position of President and Chief Executive Officer for Parkstone Medical Information Systems. Mr. Johnson returned to Johnson & Johnson in 2002 as Worldwide Vice President, CNS/Psychiatry, for Johnson & Johnson Pharmaceuticals Group Strategic Marketing. He was appointed President of Ortho Biotech Products, L.P. in March 2003, and assumed responsibility for Ortho Biotech Canada in 2004. He held this position until being named Company Group Chairman in 2005.
Mr. Johnson received a B.S. degree from East Stroudsburg University of Pennsylvania. He currently serves on the boards of BioNJ and Cempra Pharmaceuticals, Inc.
About James C. Greenwood, BIO
James C. Greenwood is President and CEO of the Biotechnology Industry Organization (BIO) in Washington, D.C., which represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
Mr. Greenwood was appointed President and CEO of BIO in January of 2005. Since that time he has markedly enhanced the trade association's capacity - increasing both its staff and budget by nearly fifty percent.
Prior to his appointment, Mr. Greenwood represented Pennsylvania's Eighth District in the U.S. House of Representatives from January 1993 through January 2005. A senior member of the Energy and Commerce Committee, he was widely viewed as a leader on health care and the environment.
From 2001 to 2004, Mr. Greenwood served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation with oversight authority over issues in the full Committee's vast jurisdiction. He led hard-hitting investigations into corporate governance at Enron, Global Crossing and WorldCom; terrorist threats to our nation's infrastructure; and waste and fraud in federal government agencies.
Prior to his election to Congress, Mr. Greenwood served six years in the Pennsylvania General Assembly (1981-86) and six years in the Pennsylvania Senate (1987-1992).
Mr. Greenwood graduated from Dickinson College in 1973 with a BA in Sociology. From 1977 until 1980, he worked as a caseworker with abused and neglected children at the Bucks County Children and Youth Social Service Agency.
About BioNJ
With 250 member companies, BioNJ is singularly focused on the growth and prosperity of New Jersey's biotechnology cluster.
Founded in 1994 by New Jersey bioscience industry CEOs, BioNJ serves as the voice of biotechnology companies located in New Jersey, seeks to advance their economic growth and development and works to encourage new and established companies from around the world to locate here. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors.
